How to Use GB-115
Complete guide to GB-115 dosing, administration, timing, and protocol recommendations.
Quick Overview
GB-115 is a synthetic dipeptide anxiolytic developed in Russia, chemically the amide of N-phenylhexanoyl-glycyl-L-tryptophan and described as a retro-analogue of cholecystokinin-4. Rather than acting like a benzodiazepine, it blocks cholecystokinin receptors, a different anti-anxiety route. It has been studied in animals and in a small pilot human study, but it is not an approved or widely available medication.
Dosing Guidelines
Common Dose
6 mg daily (2 mg three times daily)
Frequency
2-3 times daily (morning, afternoon, evening)
Dose Range
2-6 mg per day
Note: CCK-1 receptor antagonist from Russia. Clinical trial data showed 6 mg/day effective for 21-day cycles with cognitive improvements by day 7. Oral or sublingual administration. No sedation or dependency reported. Some users take 2-4 mg as needed for situational use.
Administration Method
Oral tablets or sublingual
Best Time to Take
Morning and throughout the day
Clinical trials used three times daily dosing (morning, afternoon, evening) for consistent receptor occupancy. Can be taken with or without food.
Protocol Duration
21+ days in clinical trials, effects noted by day 7
Possible Side Effects
Not everyone experiences these. Individual responses vary.
- •Generally well-tolerated
- •Minimal sedation compared to benzodiazepines
- •Headache (rare)
- •Mild gastrointestinal discomfort
- •No reported dependency or withdrawal
Frequently Asked Questions
What is the recommended dose for GB-115?
6 mg daily (2 mg three times daily)
How do you administer GB-115?
Oral tablets or sublingual
When is the best time to take GB-115?
Morning and throughout the day
How long should you use GB-115?
21+ days in clinical trials, effects noted by day 7
This information is for educational purposes only. Always consult with a healthcare professional before using any peptide. Dosing information is based on research literature and community reports, not medical advice.